Candel Therapeutics reported a significantly wider operating loss in Q3 2026 and, more critically, announced a delay in its Biologics License Application (BLA) submission for aglatimagene. This delay, pushing the timeline to mid-2027, is a negative development for investors awaiting regulatory progress and commercialization.
Candel Therapeutics disclosed a Q3 2026 operating loss of $23 million, a substantial increase from $13.2 million in Q3 2025. More significantly, the company announced a delay in its Biologics License Application (BLA) for aglatimagene in prostate cancer, pushing the submission from an unspecified earlier timeline to mid-2027 due to assay refinement and FDA discussions. This delay is a major setback for the company, as it prolongs the time to potential market entry and revenue generation for its lead candidate. While the company's cash position of $203.1 million is expected to fund operations into Q2 2028, the extended BLA timeline could lead to increased cash burn and further dilution if additional funding is needed before commercialization. For traders, this news presents a clear negative short-term catalyst for CADL stock, as regulatory delays often lead to significant share price declines, impacting investor confidence in the company's pipeline progress and future profitability.